Practice Management, Health Systems, and Quality/Safety Improvement
What this domain tests
This domain covers how pharmacy practice is organized, measured, paid for, and made safer. Expect items on medication-error taxonomy, quality-improvement methods, accreditation standards, adherence metrics, formulary management, and pharmacoeconomics.
Concepts to master
Separate a medication error (any preventable event that may cause or lead to inappropriate use or harm) from an adverse drug event (harm, whether or not preventable), and identify the phase in which it occurred - prescribing, transcribing, dispensing, administering, or monitoring. Know high-alert medications (insulin, heparin, concentrated electrolytes, opioids, chemotherapy, neuromuscular blockers) and look-alike/sound-alike risk. For improvement work, know the Model for Improvement (aim, measures, changes) driven by PDSA cycles, and distinguish retrospective root cause analysis from prospective failure mode and effects analysis. Understand just culture and why redesigning systems outperforms blaming individuals. Quality metrics include HEDIS proportion of days covered (generally PDC ≥ 0.80) and CMS Star Ratings. In pharmacoeconomics, separate cost-effectiveness (cost per QALY, ICER) from budget impact.
Common traps
Questions conflate FMEA with RCA, process measures with outcome measures, and cost-effectiveness with cost savings. PDC items tempt you to count prescriptions rather than days covered. Also expect confusion between an ADE and a potential ADE, and between regulatory requirements (USP <797>/<800>, Joint Commission standards) and merely recommended practice.
Worked example / rule of thumb
A patient receives 240 days of statin supply across a 365-day measurement year: PDC = 240/365 = 0.66, below the 0.80 threshold - the patient counts as nonadherent for the measure even though every fill was timely. Rule of thumb: adherence metrics are day-based, not fill-based.